It's hard for big pharma to justify paying a premium to take over a company with very little in terms of IP. Why pay a premium for a fledgling company with its IP that has mostly expired or is getting close to expiry?
Might as well just copy the tech and launch it under your own big brand. AVH has already lost an IP suit to a small company before. No chance against big pharma.
Shorts are increasing on AVH, page-80
-
- There are more pages in this discussion • 135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M | |||
| Open | High | Low | Value | Volume |
| $2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 980 | $2.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.76 | 10173 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |